CLINICAL_TRIALS
trial_result
· 2017-04-12
Clinical Trial Update: Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine [Phase 2]
Summary
Phase 2 open-label study assessing safety and immunogenicity of HEPLISAV hepatitis B vaccine has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dynavax Technologies Corporation | Conditions: Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2017-04-12